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Absrtact 
Breast cancer is the most common cancer among women around the world. The 
real way to improve the results of treatment of breast tumours is an early, and in 
some cases, preclinical diagnosis. This problem can only be solved if complex 
diagnostic methods are used. The aim of our work is to determine the change in the 
level of IL-10 and lactoferrin in the blood serum of patients with breast neoplasms 
corresponding to the BIRADS categories. The sensitivity, specificity, diagnostic 
values of these biochemical parameters and the correlation between them were also 
studied. According to the results of our studies, increasing levels of BIRADS 
would lead to a raise in the levels of IL-10 and lactoferrin in blood serum in 
patients with breast tumours. The results showed that lactoferrin had a high 
diagnostic value compared to IL-10. 
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Introduction 
Breast cancer (BC) is a leader in the structure of oncological diseases and mortality 
rate among female population. Survival after treatment of breast cancer, taking into 
account the quality of life and the total cost of treatment, Taking the life quality 
and treatment high cost into account, the survival of breast cancer treatment 
directly depends on the stage of the oncological process. Over the course of 
decades, X-ray mammography has been considered almost the main both screening 
and refinement method in the diagnosis of breast diseases (Amiraslanov & 
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Gaziyev, 2010). Mammography well differentiates pathological processes in the 
mammary glands with a large amount of adipose tissue on the background of 
involution. The age-related features of the architectonics of the mammary gland 
make the results of mammography in young women with a glandular structure of 
the mammary glands less convincing. To date, the possibilities of ultrasound 
diagnostics in mammology are no longer disputed. 
An ultrasound examination (ultrasound) of the mammary glands is a safe, 
affordable and highly informative method of breast examination, which is used 
both for preventive examination and for detection of various diseases of the 
mammary glands in the presence of relevant complaints (Rumack et al., 2011; 
Zabolotskaya & Zabolotsky, 1997). To standardize the assessment of the results of 
mammography, magnetic resonance imaging (MRI) and ultrasound according to 
the degree of risk of malignant  tumours of the mammary gland, the classification 
or BIRADS scale was proposed by the American Society of Radiology (American 
College of Radiology - ACR) in the late of nineties of the last century. The 
BIRADS classification is primarily aimed at facilitating interpretation of complex 
diagnostic cases in detection of neoplasms and differential diagnosis with breast 
cancer (American College of Radiology, 2003).  
With the use of modern instrumental diagnostic methods in clinical practice, the 
potential of medicine in early detection of tumours has been improved and means 
of laboratory diagnostics have significantly increased in recent years. 
It is known that the pathogenetic mechanisms of the onset and progression of 
tumour growth are the application of protein mediators - cytokines, chemokines 
and growth factors. Cytokines are secreted by both lymphoid and tumour cells, 
affecting many different target cells, and the cytokine network is the most 
important regulatory mechanism of intercellular interactions (Muftuoglu,1993). On 
the one hand, cytokines manifest themselves as factors of tumour progression 
through activating the angiogenesis and migration of tumour cells. They change 
function of target cells and are involved in the mechanism of evading tumour cells 
from the immune surveillance system. On the other hand, cytokines can be the 
main mediators of antitumor immunity. The concentration and balance of the levels 
of cytokines and their antagonists contribute to the enhancement or inhibition of 
the growth of breast cancer. Changes in the relative concentration of some 
cytokines can directly and indirectly stimulate breast cancer (Kazakov et al., 2015) 
Currently, in science and medicine, much attention is paid to antimicrobial peptides 
(AMP). The data of numerous publications devoted to the study of AMP as 
molecular factors of the innate immunity system indicate that these substances 
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have significant therapeutic potential and can be considered as candidates for the 
role of not only antimicrobial drugs, but also antitumor drugs of a new type. AMP 
are characterized by a variety of mechanisms of cytotoxic action, which can lead to 
both necrosis and apoptosis of target cells. The basis of these effects is selective 
interaction with the membranes of tumour cells, similar in a number of structural 
and physiological characteristics to the membranes of microorganisms. It has also 
been found that AMP can inhibit tumour growth through disrupting formation of its 
vascular network. Like antimicrobial activity, the antitumor effect of AMP can be 
enhanced by modulating the body's protective functions. The described properties 
of AMP give hope for development of new drugs based on which they/we can 
overcome the resistance of tumour cells (Balandin et al., 2016).  
The aim of our work was to assess the level of cytokine İL-10 and lactoferrin (LF) 
by BİRADS categories, to evaluate sensitivity, specificity and diagnostic value of 
these biochemical parameters, as well as the correlation between them. 
 
Materials and Methods 
In this work, we presented the results of a study of 92 patients undergoing 
examination for breast cancer at the Oncology Clinic of the Azerbaijan Medical 
University for the period from 2014 to 2017. The age of patients ranged from 18 to 
79 years. All patients underwent an ultrasound examination with a combination of 
dopplerography and mammography. An ultrasound examination has been 
performed by using the MINDRAY D70 device (China) and a mammography was 
conducted by using the SIEMENS MAMMOMAT INSPIRATION device 
(Germany). Out of all examined patients, 48 women were malignant and 28-benign 
breast tumours. 16 apparently healthy women have been included into the control 
group. All women have been divided into 4 groups according to the BIRADS 
category: BIRADS1, BIRADS2, BIRADS4, BIRADS5.  
In the blood of all women included in the study, serum levels of IL-10 and LF have 
been studied. The concentration of the studied parameters has been determined by 
enzyme-linked immunosorbent assay on a STAT Fax 303 Plus apparatus (USA) 
using a reagent kit of the VEKTOR – BEST firm (Russia) to define cytokines and 
Cloud-clone (China) for LF. 
The ELISA method is a highly sensitive and highly specific immunodiagnostic 
method, with the help of which a qualitative and quantitative determination of 
various substances with the properties of antigen, hapten (defective antigen) or 
antibody is carried out. The ELISA method is widely used to diagnose infectious 
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and non-infectious diseases in humans and animals and can also be used to confirm 
the quality of biological drugs. The principle of ELISA consists in the specific 
interaction of an antigen and an antibody, creation of an Ag/Ab complex and a 
conjugate, and determination of a resulting complex according to the degree of 
colour by using a substrate mixture.  
To calculate the sensitivity, specificity and diagnostic value of tumour markers and 
cytokines a “cut of point” has been determined in SOCS-20 by using ROC analysis 
in advance and statistical parameters calculated in binary classification with respect 
to this point in MS EXCEL-2013.  
 
Results and discussion  
IL-10 is an anti-inflammatory cytokine. During infection, it inhibits the activity of 
Th1 cells, NK cells, and macrophages, all of which are required for optimal 
pathogen clearance but also contribute to tissue damage. In consequence, IL-10 can 
both impede pathogen clearance and ameliorate immunopathology (Couper et al., 
2008). As a result of our studies, it was revealed that in women included in the 
BIRADS 1 category, the level of IL-10 ranged from 2.8-9.5 ng/ml, averaging 6.13 
ng/ml (Table 1). In the BIRADS 2 group, the level of this indicator was 3.8-16.2 
ng/ml, an average of 8.77 ng/ml (p <0.05). In patients included in the BIRADS 4 
category, the level of IL-10 averaged 6.13 ng/ml, min and max levels were 
respectively 5.4-19.1 ng/ml (p <0.001). In the BIRADS 5 category, the level of IL-
10 ranged between 7.5-23.2 ng/ml, averaging 14.78 ng/ml (p <0.001). 
Table 1. The level of IL-10 in breast tumours according to BIRADS classification 
According to our data, in women included in the BIRADS 2 group, in comparison 
with the control group, the level of İL-10 increased 1.43 times, and in the BIRADS 
 N Mean 
Std. 
Deviation 
Std. 
Error 
95% Confidence 
Interval for Mean 
Min. Max. 
Lower 
Bound 
Upper 
Bound 
Il-
10 
B1 16 6,13 2,20 0,55 4,96 7,30 2,8 9,5 
B2 19 8,77 3,56 0,82 7,05 10,48 3,8 16,2 
B4 26 10,47 4,34 0,85 8,72 12,22 5,4 19,1 
B5 31 14,78 4,73 0,85 13,04 16,51 7,5 23,2 
Total 92 10,82 5,09 0,53 9,76 11,87 2,8 23,2 
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4 and BIRADS 5 groups the level of this cytokine was even higher and increased 
1.7 and 2.4 times respectively.  
 
Figure 1. The level of IL-10 in neoplasms of the breast according to the 
classifications BIRADS 
Interleukin-10, which has an important coordinated role in breast carcinogenesis 
(Sheikhpour & Mohiti, 2014), is an anti-inflammatory cytokine that regulates the 
immune response and inhibits the pro-inflammatory functions of antigen-
presenting cells (APCs) through expression of antagonizing costimulatory 
molecules. Its low expression is associated with poor survival outcome. The role of 
IL-10 in breast cancer is controversial. Interleukin -10 has both pro- and anti-tumor 
effects. IL-10 mRNA expression is seen in more than 50% of tumor samples. Also, 
greater IL-10 protein concentrations are seen in serum of breast cancer patients 
than in that of healthy individuals and this is associated with poor clinical 
outcomes. Interleukin-10 promoted proliferation and metastasis of tumor cells and 
inhibited T-cell proliferation and function (Li et al., 2014; Fernandez, 2006; 
Sheikhpour et al., 2018).  
We also determined the level of LF in the blood serum of patients with breast 
neoplasms according to the BIRADS categories (Table 1). In the BIRADS group 1, 
the LF level ranged from 0.9-5.8 ng/ml, averaging 3.26 ng/ml. In women included 
in the BIRADS 2 category, the average level of this indicator was 5.81 ng/ml, the 
interval of variation was 1.9-9.2 ng / ml. In the BIRADS 4 min and max categories, 
the indicators were 5.1 and 18.8 ng / ml, respectively, the average level was 10.24 
ng/ml (p<0.001). In patients included in the BIRADS 5 group, the LF value ranged 
between 8.2-42.7 ng/ml, the average level was 30.84 ng/ml (Figure 2).  
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As compared with the control group, in women included in the BIRADS 2 group, 
the LF value increased 1.78 times, and in the BIRADS4 and BIRADS 5 groups the 
level of this indicator increased 3.14 and 9.5 times, respectively. 
Table 2. LF level in case of breast neoplasms according to BIRADS classification. 
  N Mean 
Std. 
Deviation 
Std. 
Error 
95% Confidence 
Interval for Mean 
M
in
im
u
m
 
M
ax
im
u
m
 
Lower 
Bound 
Upper 
Bound 
LF B1 16 3,26 1,37 0,34 2,53 3,99 0,9 5,8 
B2 19 5,81 2,41 0,55 4,65 6,97 1,9 9,2 
B4 26 10,24 3,66 0,72 8,76 11,72 5,1 18,8 
B5 31 30,84 9,41 1,69 27,39 34,29 8,2 42,7 
Total 92 15,05 12,97 1,35 12,37 17,74 0,9 42,7 
 
 
Figure 2. LF level in case of breast neoplasms according to BIRADS classification 
Lactoferrin (LF) has a direct effect on cell growth, due to which it can act as a 
regulatory element in protecting the body from the development of tumours and 
metastases. The protein has a direct effect on the growth of tumour cells, which is 
confirmed by the slowdown or lack of splicing of its mRNA in cancer cells. LF 
blocks transition from G1 to S stage of the cell cycle (Borzenkova et al., 2010).  It 
adversely affects cell proliferation, causing changes in the expression and/or 
activity of important regulatory cell cycle proteins. By activating the signaling 
pathway of fatty acid synthase in cancer cells, the protein induced apoptosis. In 
addition, LF stimulates the production and/or activation of various immune cells 
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including lymphocytes and normal killer cells, and also increases the sensitivity of 
target cells to lysis by killer cells (Balandin, 2016; Naidu, 2010).   
In our work, we also evaluated the sensitivity, specificity, and diagnostic value of 
IL-10 and LF. According to our data, the sensitivity of IL-10 in assessing the 
malignancy of a breast tumour was 60.4 ± 7.1%, and specificity was 78.6 ± 7.8%. 
The predictive usefulness of a positive result was 82.9 ± 6.4%, the predictive 
usefulness of a negative result was 53.7 ± 7.8%. The likelihood ratio of a positive 
result was 2.82 and was assessed as mediocre, and a negative result of 0.50 and 
assessed as unsuitable. The total diagnostic weight of the test was 67.1 ± 5.4%. 
In the course of studies, it was found that the sensitivity of the LF in assessing the 
malignancy of a breast tumour was 83.3±5.4%, and the specificity was– 
85.7±6.6%. The predictive usefulness of a positive result was 90.9±4.3%, the 
predictive usefulness of a negative results was 75.0±7.7%. The likelihood ratio of a 
positive result was 5.83 and a negative result of 0.19 and both parameters were 
rated as good. The total diagnostic weight of the test was 84.2±4.2%. 
Table 2. The sensitivity and specificity of the cytokines IL-10 and LF in breast 
tumors 
 Se, % Sp, % pPV, % nPV, % LR+ LR- 
IL-10 60,4±7,1 78,6±7,8 82,9±6,4 53,7±7,8 2,82 0,50 
LF 83,3±5,4 85,7±6,6 90,9±4,3 75,0±7,7 5,83 0,19 
It should also be noted that in the course of our studies, a statistically significant 
positive correlation was observed between IL-10 and lactoferrin (ρ=0.645, 
p˂0.001).  
Taking into account the results of our study we can conclude that these data may 
serve in the diagnosis and monitoring of breast cancer treatment. 
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